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The Effects of Rolipram, a Selective Phosphodiesterase Inhibitor, on Immortalized Schwann 
Cell Proliferation, AKAP95 and Cyclin D3 Expression
Kyle Kenney*, Mary Pistack, and Angela Asirvatham 
Department of Biology, Misericordia University Dallas, Pennsylvania 
Introduction: Schwann cells are a vital component of the peripheral nervous system (PNS) due to their ability to 
protect and myelinate axons in addition to aiding in neural repair. Schwann cell differentiation, proliferation, and 
migration at the site of injury depends on the levels of intracellular cyclic adenosine monophosphate (cAMP).1
When intracellular cAMP levels are low, Schwann cells exhibit a myelinating phenotype while high concentrations 
result in a proliferating phenotype.2 Due to this capability, Schwann cell transplants have been attempted to treat 
damaged nervous tissue found in both the PNS and the central nervous system (CNS). In the CNS, due to inadequate 
growth and cell signaling factors, there is little success with these transplants.3 The regulation of Schwann cell 
growth in vitro is facilitated by heregulin, a neuron-secreted growth factor, and an unknown mitogen that activates 
the cAMP pathway.3,4 In recent years, researchers have used phosphodiesterase inhibitors as an alternative form of 
treatment for spinal cord damage, multiple sclerosis, Alzheimer’s Disease, and other neurodegenerative diseases. 
Phosphodiesterase inhibitors increase the abundance of intracellular cAMP in Schwann cells by targeting and 
hydrolyzing phosphodiesterases (PDEs) a family of enzymes responsible for the regulation of the universal 
secondary messenger.5,6 Besides inducing increased rates of cell proliferation, intracellular cAMP binds to the 
regulatory subunit of Protein Kinase-A (PKA) which releases the catalytic subunits to phosphorylate protein 
substrates. A-Kinase anchoring proteins (AKAPs) are a family of scaffolding proteins that anchor PKA and bind to 
PDEs and regulate cAMP concentration in cardiac myocytes. Previous studies have shown that AKAP95, a nuclear 
AKAP, known for scaffolding cyclins, is essential for Schwann cell growth.7,8 Currently there is no literature that 
explores the effects of phosphodiesterase inhibitors such as rolipram on Schwann cells proliferation, AKAP95, and 
cyclin D3 expression. Based on these reports, it was hypothesized that increasing the concentration of rolipram 
would elicit a dose-dependent increase in Schwann cell proliferation by augmenting the expression of AKAP95 and 
cyclin D3. 
Conclusions:
ØCells treated with 5 μM of rolipram at 12 hours and 1 μM of rolipram at 24 hours expressed the 
greatest amount of proliferation.
ØCells cultured with heregulin and forskolin and 50 μM rolipram exhibited an upregulation of AKAP95 
at 12 hours (p<0.05).
ØCells cultured with forskolin 25 μM rolipram, and heregulin and forskolin and 50 μM rolipram 
exhibited an upregulation of cyclin D3 at 12 hours (p<0.05).
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Schwann cell morphology in response to rolipram:
Figure 2 – S 16 Schwann cell were cultured in control media (N2), 12.5 ng/mL heregulin (Hrg), 1 μM forskolin (Fsk), heregulin + forskolin (Hrg + Fsk) at 37 ℃ and 
5% CO2. Cells were also incubated with various dosages of rolipram as specified above for cell proliferation assay. Cells treated with 5 μM of rolipram at 12 hours 
and 1 μM of rolipram at 24 hours expressed the greatest amount of proliferation while cells treated with more than 5 μM of rolipram revealed a decrease in cell 
number and proliferation. The above result is one representative set of images from a 12-hour incubation of rolipram. The experiment contained three 
independent trails for 12-hours and four for 24-hours.
AKAP95 and cyclin D3 expression 
Figure 5 – Quantitative analysis of AKAP95 and cyclin D3 expression as analyzed by 
densitometry is shown above. Protein expression was normalized with signal intensities of 
actin protein and expressed as percent control over basal levels of unstimulated cells and 
displayed as the mean + SEM. Results from all three experiments were examined using one-
way ANOVA and tested with post hoc Tukey test. The cells were treated for 12 hours. The 
cells cultured with heregulin plus forskolin and 50 μM rolipram exhibited an upregulation of 
AKAP95. Cells cultured with forskolin 25 μM rolipram, and heregulin plus forskolin and 50 
μM rolipram exhibited an upregulation of cyclin D3 (n=3, p<0.05).
Schwann cell proliferation in response to rolipram
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Figure 3 – S16 Schwann cells were seeded 50,000 cells per well using a 96 well plate until they reached 80% confluency. Cells were incubated in colorless control (N2) media for 24 hours then cultured with no 
mitogens (figure 2A), 12.5 ng/mL heregulin (figure 2B), 1 μM forskolin (figure 2C), heregulin + forskolin (figure 2D), and various concentrations of rolipram ranging from 0 μM to 50 μM for either 12 hours or 24 
hours. Cell proliferation and survival was measured using VybrantTM MTT cell proliferation assays with the means + SEM displayed. Statistical analysis using one-way ANOVA revealed that overall, there was no 
significantly different effects between timepoints. However, using a post-hoc Tukey test, the following groups were statistically significant at P < 0.05 (Table 1). Replicates for the 12-hour MTT assay were repeated 
three times and 24-hour MTT assay were repeated four times.
Time Treatments P-Value
12 Hrs Hrg + Fsk at 50 μM R was significant to Fsk at 0.5 μM R 0.03
12 Hrs Hrg + Fsk at 50 μM R was significant to Fsk at 1 μM R 0.033
12 Hrs Hrg + Fsk at 50 μM R was significant to Hrg + Fsk at 0.5 μM R  0.042
12 Hrs Hrg + Fsk at 50 μM R was significant to Hrg + Fsk at 1 μM R 0.022
24 Hrs N2 at 0.5 μM R was significant to Fsk at 50 μM R 0.021
24 Hrs N2 at 0.5 μM R was significant to Hrg + Fsk at 10 μM R 0.025
24 Hrs N2 at 0.5 μM R was significant to Hrg + Fsk at 50 μM R 0.038
24 Hrs Hrg + Fsk at 0.5 μM R was significant to Fsk at 50 μM R 0.025
24 Hrs Hrg + Fsk at 0.5 μM R was significant to Hrg + Fsk at 10 μM R 0.021
24 Hrs Hrg + Fsk at 0.5 μM R was significant to Hrg + Fsk at 50 μM R 0.024
Table 1 - Table of P-Values of rolipram treatment groups that elicited 
statistical significance
AKAP95, cyclin D3, and actin Immunoblots
Figure 4 - S16 Schwann cells (ATCC) were treated with no mitogens (N2), heregulin (Hrg) at 12.5 ng/mL, 
forskolin (Fsk) at 1 μM, heregulin + forskolin(Hrg + Fsk), and various concentrations of the phosphodiesterase 
inhibitor rolipram, ranging from 0 μM to 50 μM for 12-hours. The expression of AKAP95 and cyclin D3 were 
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Figure 1 – This is a cartoon depiction of the cAMP and PKA pathways in the cell.
cAMP-PKA Signaling Pathway




v Schwann cell culturing: Schwann cell line CRL-2941 (ATCC) was purchased and cultured in Dulbecco’s Modified 
Eagle Media (DMEM), 10% Fetal Bovine Serum (FBS), and 1% 1/1 penicillium:streptomycin at 37 ℃ and 5% CO2 
until 80% confluency and were continuously sub-cultured. 
v MTT Assay: For 12 and 24-hour MTT assays, 50,000 cells were seeded per well in a 96 well plate with colorless 
DMEM until 85% confluent. Cells were then treated with no mitogen (N2) media for 24-hours and received the 
following treatments: control media (N2), 12.5 ng/mL heregulin (Hrg), 1 μM forskolin (Fsk), or heregulin + forskolin 
(Hrg + Fsk) with various doses of rolipram (0, 0.5, 1, 5, 10, 25, or 50 μM). Prior to the Vybrant MTT assay, Schwann 
cell morphology was visualized at 10X magnification using a Zeiss Primovert microscope and Axiocam ER c5S 
camera attachment. After incubation, cell viability was determined by reading the optical absorbance at 570 nm.
v AKAP95 and cyclin D3 exxpression: S16 Schwann cells (ATCC) were treated with no mitogens (N2), heregulin (Hrg) 
at 12.5 ng/mL, forskolin (Fsk) at 1 μM, heregulin + forskolin(Hrg + Fsk), and various concentrations of the 
phosphodiesterase inhibitor rolipram, ranging from 0 μM to 50 μM for 12-hours at 37 ℃ and 5% CO2. 
Cell extracts were prepared, processed, ran in polyacrylamide gels, and transferred onto 
nitrocellulose membranes. The expression of AKAP95 and cyclin D3 were then
analyzed by performing western blots and normalizing with actin. 
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